Which factor influences the cardiovascular risk associated with hormone therapy?

Which factor influences the cardiovascular risk associated with hormone therapy?

• A. Route of administration is the only factor.
• B. Smoking status alone.
• C. Timing of initiation relative to menopause.
• D. Age at menopause has no effect.

Answer: (C)

The key idea is that when you start hormone therapy relative to menopause changes how your cardiovascular system responds. This is the timing effect: estrogen can help maintain vascular function and a favorable lipid profile when begun near menopause, potentially slowing early atherosclerosis. But starting therapy many years after menopause—when vascular disease is more likely already present—can lessen benefits and increase risks such as heart attack, stroke, or blood clots. So timing of initiation relative to menopause is the most influential factor for cardiovascular risk with hormone therapy. Route of administration and smoking or other factors can modify risk, but they don’t override the impact of when therapy is started.

The key idea is that when you start hormone therapy relative to menopause changes how your cardiovascular system responds. This is the timing effect: estrogen can help maintain vascular function and a favorable lipid profile when begun near menopause, potentially slowing early atherosclerosis. But starting therapy many years after menopause—when vascular disease is more likely already present—can lessen benefits and increase risks such as heart attack, stroke, or blood clots. So timing of initiation relative to menopause is the most influential factor for cardiovascular risk with hormone therapy. Route of administration and smoking or other factors can modify risk, but they don’t override the impact of when therapy is started.